Claritas Pharmaceuticals Inc
XTSX:CLAS
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
C
|
Claritas Pharmaceuticals Inc
XTSX:CLAS
|
10.4m CAD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
964.4B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
572.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
282.5B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
297.7B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.5B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
227.6B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151.1B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.9B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Claritas Pharmaceuticals Inc
Glance View
Claritas Pharmaceuticals, Inc. engages in the development of next generation cannabinoid therapeutics. The company is headquartered in Novato, California. The company went IPO on 2005-05-19. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The firm has leased a laboratory, office, and archival space in Beverly, Massachusetts.
